Evaluation of CYP2C19 Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in Guangxi
DOI: https://doi.org/10.2147/pgpm.s457805
2024-05-15
Pharmacogenomics and Personalized Medicine
Abstract:Jun Mei Teng, 1 Shuiqing Qin, 2 Danyu Lu, 1 Yefa Gu, 3 Shi Jie Tang, 3 Qiong Yan, 1 Jiawei Yao, 1 Chao Zhang 1 1 Laboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China; 2 Department of Science and Education, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China; 3 Department of Psychiatry, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China Correspondence: Danyu Lu, Laboratory Department, The Fifth People's Hospital of Nanning, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China, Tel +86 13457087740, Email Purpose: To investigate the CYP2C19 genotype distribution and allelic frequency among the Zhuang and Han schizophrenic populations in Guangxi, examine the correlation between CYP2C19 genetic variants and standardized blood levels of Valproic Acid (VPA) in schizophrenic patients, and evaluate the effects of age, gender, and Body Mass Index (BMI) on standardized VPA blood concentrations. Patients and Methods: Between February and December 2022, 192 Zhuang and Han schizophrenia patients treated with VPA were studied. Steady-state VPA concentrations were determined using homogeneous enzyme immunoassays, and CYP2C19 &ast1, &ast2, and &ast3 loci via q-PCR. CYP2C19 genotype distributions between Zhuang and Han groups in Nanning were compared using chi-square tests and contrasted with other ethnicities. Non-parametric tests analyzed VPA variations, identifying critical factors through multivariate stepwise regression. Results: The study identified five CYP2C19 genotypes at the &ast2 and &ast3 loci, with the &ast3/&ast3 genotype absent in both cohorts. The CYP2C19 distribution in Guangxi Zhuang and Han mirrors, yet diverges significantly from Hui and Kazakh groups. Among 192 subjects, VPA blood levels remained consistent across metabolic types and ages 18– 60 but varied significantly by gender. Multivariate analysis revealed gender and BMI as significant factors, overshadowing CYP2C19 genotype and age. Conclusion: In Guangxi, CYP2C19 genetic variants in Zhuang and Han schizophrenia patients demonstrate statistically indistinguishable allelic and metabolic distributions. Gender and BMI can influence standardized VPA blood concentrations in schizophrenia patients. However, in our study cohort, the CYP2C19 genotype and age are not the primary determinants of standardized VPA blood levels. Keywords: CYP2C19 gene, valproic acid, blood drug concentration, Zhuang Chinese, Han Chinese Pharmacogenomics delves into the intricate interplay between human genomic information and drug responses, with the ultimate goal of elucidating the variations in drug safety and efficacy among individuals. 1–3 As a pivotal facet of precision medicine, pharmacogenomics is centrally concerned with meticulous drug and dosage selection, targeted therapeutic interventions, and the anticipation of drug safety concerns, all while mitigating the emergence of deleterious side effects. This avenue of research empowers us to prognosticate patient responses to specific medications, thereby paving the way for bespoke treatment regimens. 4,5 The metabolism kinetics and therapeutic potency of drugs are frequently orchestrated by endogenous enzymes, under the orchestration of genes. In instances where distinct genetic variants manifest, their impact on drug effects and safety can be discernible. For instance, the CYP2C19 gene encodes a member of the cytochrome P450 enzyme family, playing a pivotal role in drug metabolism. 6,7 This encompassing enzymatic responsibility extends to an array of pharmaceuticals, including certain antifungal agents, antidepressants, proton pump inhibitors, and antiplatelet aggregation medications. 8–11 The CYP2C19 enzyme, owing to its intricate genetic diversity, has emerged as a focal point in pharmacogenomic investigations, wherein these genetic variances may conceivably modulate enzyme functionality and drug metabolism. 12 Notably, the CYP2C19 allele denoted as CYP2C19 *17, endowed with an augmenting influence on enzyme activity, might necessitate a commensurate escalation in drug dosages to attain therapeutic outcomes. Conversely, aberrant CYP2C19 alleles, such as CYP2C19 *2 and CYP2C19 *3, could engender protracted metabolism, thus heightening the susceptibility to adverse effects, as expounded in the Clinica -Abstract Truncated-
pharmacology & pharmacy